JuvisƩ to market, develop Ponvory outside North America
The French company JuvisĆ© Pharmaceuticals has acquired the rights to develop and market the approved multiple sclerosis (MS) therapy Ponvory (ponesimod) outside the U.S. and Canada. The global rights were acquired from Actelion Pharmaceuticals, the therapy’s original developer and now part of JohnsonĀ &Ā Johnson Innovative Medicine.